Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model

Herman S Cheung, John D. Sallis, Konstantino D. Demadis, Andrzej Wierzbicki

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective. Calcium deposition occurs frequently in osteoarthritic (OA) joints. However, evidence for a causal role of calcification in cartilage degeneration is inferential. The present study was undertaken to examine the role of calcification in OA disease progression and to evaluate a formulation of phosphocitrate (PC) as a potential therapeutic agent. Methods. We have identified a guinea pig OA model in which meniscal calcification appears to correlate with aging and disease progression. We synthesized a new formulation of PC, [CaNa(PC)2(H2O)]n (CaNaPC), which is a potent antimineralization agent and a specific inhibitor of crystal-induced biologic effects. After weekly treatment of guinea pigs with experimental OA with CaNaPC for 3 months, we examined calcification in menisci and cartilage degeneration. As a control, we examined whether similar CaNaPC treatment had any therapeutic effect in a hemi-meniscectomy model in which there is no known crystal involvement. Results. Meniscal calcification correlated with cartilage degeneration in this animal model. PC treatment led to significant reduction of calcium deposits and arrested OA disease progression. Similar treatment had no effect in the hemi-meniscectomy model. Conclusion. CaNaPC diminishes mineralization in a cutaneous calcergy model and a model of OA in which intraarticular mineralization is a prominent feature. In the OA guinea pig model, inhibition of calcification is accompanied by diminished cartilage degeneration. CaNaPC has no therapeutic effect in the hemimeniscectomy model. We conclude that pathologic calcification may initiate or amplify processes leading to cartilage degeneration and that CaNaPC may interrupt such a pathway.

Original languageEnglish
Pages (from-to)2452-2461
Number of pages10
JournalArthritis and Rheumatism
Volume54
Issue number8
DOIs
StatePublished - Aug 1 2006

Fingerprint

Cartilage
Guinea Pigs
Joints
Disease Progression
Therapeutic Uses
Calcium
Calcinosis
Animal Models
phosphocitrate
Skin
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model. / Cheung, Herman S; Sallis, John D.; Demadis, Konstantino D.; Wierzbicki, Andrzej.

In: Arthritis and Rheumatism, Vol. 54, No. 8, 01.08.2006, p. 2452-2461.

Research output: Contribution to journalArticle

Cheung, Herman S ; Sallis, John D. ; Demadis, Konstantino D. ; Wierzbicki, Andrzej. / Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 8. pp. 2452-2461.
@article{1e87897450ce40a590fec5d9fbab1a75,
title = "Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model",
abstract = "Objective. Calcium deposition occurs frequently in osteoarthritic (OA) joints. However, evidence for a causal role of calcification in cartilage degeneration is inferential. The present study was undertaken to examine the role of calcification in OA disease progression and to evaluate a formulation of phosphocitrate (PC) as a potential therapeutic agent. Methods. We have identified a guinea pig OA model in which meniscal calcification appears to correlate with aging and disease progression. We synthesized a new formulation of PC, [CaNa(PC)2(H2O)]n (CaNaPC), which is a potent antimineralization agent and a specific inhibitor of crystal-induced biologic effects. After weekly treatment of guinea pigs with experimental OA with CaNaPC for 3 months, we examined calcification in menisci and cartilage degeneration. As a control, we examined whether similar CaNaPC treatment had any therapeutic effect in a hemi-meniscectomy model in which there is no known crystal involvement. Results. Meniscal calcification correlated with cartilage degeneration in this animal model. PC treatment led to significant reduction of calcium deposits and arrested OA disease progression. Similar treatment had no effect in the hemi-meniscectomy model. Conclusion. CaNaPC diminishes mineralization in a cutaneous calcergy model and a model of OA in which intraarticular mineralization is a prominent feature. In the OA guinea pig model, inhibition of calcification is accompanied by diminished cartilage degeneration. CaNaPC has no therapeutic effect in the hemimeniscectomy model. We conclude that pathologic calcification may initiate or amplify processes leading to cartilage degeneration and that CaNaPC may interrupt such a pathway.",
author = "Cheung, {Herman S} and Sallis, {John D.} and Demadis, {Konstantino D.} and Andrzej Wierzbicki",
year = "2006",
month = "8",
day = "1",
doi = "10.1002/art.22017",
language = "English",
volume = "54",
pages = "2452--2461",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Phosphocitrate blocks calcification-induced articular joint degeneration in a guinea pig model

AU - Cheung, Herman S

AU - Sallis, John D.

AU - Demadis, Konstantino D.

AU - Wierzbicki, Andrzej

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Objective. Calcium deposition occurs frequently in osteoarthritic (OA) joints. However, evidence for a causal role of calcification in cartilage degeneration is inferential. The present study was undertaken to examine the role of calcification in OA disease progression and to evaluate a formulation of phosphocitrate (PC) as a potential therapeutic agent. Methods. We have identified a guinea pig OA model in which meniscal calcification appears to correlate with aging and disease progression. We synthesized a new formulation of PC, [CaNa(PC)2(H2O)]n (CaNaPC), which is a potent antimineralization agent and a specific inhibitor of crystal-induced biologic effects. After weekly treatment of guinea pigs with experimental OA with CaNaPC for 3 months, we examined calcification in menisci and cartilage degeneration. As a control, we examined whether similar CaNaPC treatment had any therapeutic effect in a hemi-meniscectomy model in which there is no known crystal involvement. Results. Meniscal calcification correlated with cartilage degeneration in this animal model. PC treatment led to significant reduction of calcium deposits and arrested OA disease progression. Similar treatment had no effect in the hemi-meniscectomy model. Conclusion. CaNaPC diminishes mineralization in a cutaneous calcergy model and a model of OA in which intraarticular mineralization is a prominent feature. In the OA guinea pig model, inhibition of calcification is accompanied by diminished cartilage degeneration. CaNaPC has no therapeutic effect in the hemimeniscectomy model. We conclude that pathologic calcification may initiate or amplify processes leading to cartilage degeneration and that CaNaPC may interrupt such a pathway.

AB - Objective. Calcium deposition occurs frequently in osteoarthritic (OA) joints. However, evidence for a causal role of calcification in cartilage degeneration is inferential. The present study was undertaken to examine the role of calcification in OA disease progression and to evaluate a formulation of phosphocitrate (PC) as a potential therapeutic agent. Methods. We have identified a guinea pig OA model in which meniscal calcification appears to correlate with aging and disease progression. We synthesized a new formulation of PC, [CaNa(PC)2(H2O)]n (CaNaPC), which is a potent antimineralization agent and a specific inhibitor of crystal-induced biologic effects. After weekly treatment of guinea pigs with experimental OA with CaNaPC for 3 months, we examined calcification in menisci and cartilage degeneration. As a control, we examined whether similar CaNaPC treatment had any therapeutic effect in a hemi-meniscectomy model in which there is no known crystal involvement. Results. Meniscal calcification correlated with cartilage degeneration in this animal model. PC treatment led to significant reduction of calcium deposits and arrested OA disease progression. Similar treatment had no effect in the hemi-meniscectomy model. Conclusion. CaNaPC diminishes mineralization in a cutaneous calcergy model and a model of OA in which intraarticular mineralization is a prominent feature. In the OA guinea pig model, inhibition of calcification is accompanied by diminished cartilage degeneration. CaNaPC has no therapeutic effect in the hemimeniscectomy model. We conclude that pathologic calcification may initiate or amplify processes leading to cartilage degeneration and that CaNaPC may interrupt such a pathway.

UR - http://www.scopus.com/inward/record.url?scp=33746960228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746960228&partnerID=8YFLogxK

U2 - 10.1002/art.22017

DO - 10.1002/art.22017

M3 - Article

C2 - 16869019

AN - SCOPUS:33746960228

VL - 54

SP - 2452

EP - 2461

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -